Interview with Odnir Finotti, Executive President, Pró Genéricos
When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote…
Address: Rua Alvorada, 1280
CEP : 04550-004
Rua Alvorada, 1280 CEP : 04550-004 São Paulo – SP,Brazil
Tel: (11) 3897-9767
Web: http://www.progenericos.org.br/
Founded in January 2001, the Brazilian Association of Generic Drugs – Pró Genéricos brings together leading laboratories working in the production and marketing generic drugs in the country.
Pró Genéricos is a nonprofit entity whose main mission is to contribute to the improvement of access to medicines in Brazil through the consolidation and expansion of the generics market.
Together, the members of the Pro Generic constitutes around 90% of sales in the generics business in the country. Pro Generic connects various sectors of society, institutions of public and private channels with the actions of its members, giving substance to public debate on issues relevant to the health sector and the development of the pharmaceutical industry in the country .
Since September 2005, Pró Genéricos has been part of the Generic IGPA (International Generic Pharmaceutical Alliance), as an observer. Founded in March 1997, the IGPA is an international organization that seeks to ensure consumer access to medicines that meet quality and economy.
Industry Association.
When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote…
After a globe-trotting career that led him to diverse global affiliates, the long-term Takeda executive Rodrigo Rodriguez is going full circle. Returning to where he began his career at the…
A roundup of the biggest stories from Brazil’s pharma industry, including Teuto’s cannabis manufacturing deal with MediPharm; Eurofarma’s AI-based epilepsy joint venture with SK Biopharmaceuticals; EMS’s increased stake in Hypera…
With the largest public healthcare system in the world, Latin America’s biggest pharma market, its leading regulatory body, and a huge and diverse population, Brazil is a strategic destination for…
For the second consecutive year, DIA Europe hosted a Latin America Town Hall, a panel discussion to foster collaboration and share updates from regulatory activities in Latin America and Europe,…
An overview of some of the biggest stories from Latin American pharma and healthcare, including Brazil’s rollout of dengue vaccines following a sharp increase in cases; the Brazilian regulatory agency…
A roundup of some of the latest stories from Latin American pharma and healthcare, including Sanfer’s acquisition of Columbia-based injectables manufacturer Vitalis; medicine shortages in Colombia, and Chile’s move towards…
Brazil’s ANVISA is commonly recognised as LatAm’s leading national medicines regulator and is defined by the Pan American Health Organization (PAHO) as a National Regulatory Authority of Regional Reference (NRAr) for medicines…
The latest pharma news from Brazil, including the partnership between Biophytis and Innovation Solutions Pharma; Merck’s 100 years in Brazil; Eurofarma’s USD 100 million biotech investment, and GSK’s green light…
A roundup of some of the latest news from Latin American pharma, including Acino’s acquisition of M8 Pharmaceuticals; AstraZeneca’s growth in Mexico; Neuraxpharm’s expansion into Brazil and Mexico, and Columbia’s…
The DIA Global Annual Meeting 2023 hosted DIA’s first regulatory Town Hall fully dedicated to one regulator from Latin America, as leadership from Brazil’s Health Regulatory Agency, ANVISA, shared updates on the…
The latest pharma news from Brazil, including Daiichi Sankyo’s new plant; Bristol Myers Squibb’s re-entry into Brazil’s cardiology market; the Anvisa approval of HIV prevention drug, cabotegravir; Merck’s gamble on…
A vibrant and diverse continent, home to over 650 million people and the highest life expectancy among developing regions, Latin America is now emerging as a globally relevant life sciences…
See our Cookie Privacy Policy Here
